Progressive familial intrahepatic cholestasis: Genetic disorders of biliary transporters

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 6, 2005, Pages 807-817

  Harris, Matthew J ^a   Le Gouteur, David G ^a   Arias, Irwin M ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

ABC transporters; Biliary secretion; Hereditary cholestasis; Intrahepatic; PFIC

Indexed keywords

5' NUCLEOTIDASE; ABC TRANSPORTER; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; AMINOPHOSPHOLIPID; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILE SALT; BILIRUBIN; CARRIER PROTEIN; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLESTYRAMINE; CORTICOSTEROID; FARNESOID X RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 3; PHENOBARBITAL; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID TRANSFER PROTEIN; PHOSPHOLIPID TRANSLOCASE; PREGNANE X RECEPTOR; RETINOL; RIFAMPICIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN K GROUP;

ANIMAL MODEL; AUTOSOMAL RECESSIVE INHERITANCE; BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS; BILE SECRETION; BILIRUBIN BLOOD LEVEL; CHROMOSOME 18Q; CHROMOSOME 2Q; CHROMOSOME 7Q; CLINICAL FEATURE; DIARRHEA; ENTEROHEPATIC CIRCULATION; FAILURE TO THRIVE; FAMILIAL DISEASE; FAMILY HISTORY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; HEARING LOSS; HEPATOMEGALY; HUMAN; ILEUM BYPASS; INTRAHEPATIC CHOLESTASIS; JAUNDICE; KNOCKOUT MOUSE; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LOW FAT DIET; MALABSORPTION; MOUSE; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 2; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 3; PRURITUS; REVIEW; SPLENOMEGALY; VITAMIN DEFICIENCY;

EID: 21244440246     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03743.x     Document Type: Review

References (79)

1. Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease: fatal familial intrahepatic cholestasis in an Amish kindred. J. Pediatr. 1965; 67: 1025-8.
2. Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am. J. Dis. Child. 1969; 117: 112-24.
3. Toussaint W, Gros H. [Familial jaundice caused by intrahepatic cholestasis]. Dtsch. Z. Verdau. Stoffwechselkr. 1966; 26: 23-31.
4. Williams CN, Kaye R, Baker L, Hurwitz R, Senior JR. Progressive familial cholestatic cirrhosis and bile acid metabolism. J. Pediatr. 1972; 81: 493-500.
5. Gray OP, Saunders RA. Familial intrahepatic cholestatic jaundice in infancy. Arch. Dis. Child. 1966; 41: 320-8.
6. Hirooka M, Ono T. A case of familial intrahepatic cholestasis. Tohoku J. Exp. Med. 1968; 94: 293-306.
7. Oshima T, Ikeda K, Takasaka T. Sensorineural hearing loss associated with Byler disease. Tohoku J. Exp. Med. 1999; 187: 83-8.
8. Lloyd-Still JD. Familial cholestasis with elevated sweat electrolyte concentrations. J. Pediatr. 1981; 99: 580-3.
9. Hillemeier AC, Hen J Jr, Riely CA, Dolan TF Jr, Gryboski JD. Meconium peritonitis and increasing sweat chloride determinations in a case of familial progressive intrahepatic cholestasis. Pediatrics 1982; 69: 325-7.
10. Bourke B, Goggin N, Walsh D, Kennedy S, Setchell KD, Drumm B. Byler-like familial cholestasis in an extended kindred. Arch. Dis. Child. 1996; 75: 223-7.
11. van Mil SW, Klomp LW, Bull LN, Houwen RH. FIC1 disease: a spectrum of intrahepatic cholestatic disorders. Semin. Liver Dis. 2001; 21: 535-44.
12. Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF. Histologic pathology of the liver in progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 1994; 18: 128-33.
13. Bull LN, Carlton VE, Stricker NL et al. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology 1997; 26: 155-64.
14. Carlton VE, Knisely AS, Freimer NB. Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q22, the benign recurrent intrahepatic cholestasis region. Hum. Mol. Genet. 1995; 4: 1049-53.
15. Bull LN, van Eijk MJ, Pawlikowska L et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 1998; 18: 219-24.
16. Klomp LW, Bull LN, Knisely AS et al. A missense mutation in FIC1 is associated with greenland familial cholestasis. Hepatology 2000; 32: 1337-41.
17. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 2003; 278: 49965-71.
18. Ujhazy P, Ortiz D, Misra S et al. Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology 2001; 34: 768-75.
19. Tang X, Halleck MS, Schlegel RA, Williamson P. A subfamily of P-type ATPases with aminophospholipid transporting activity. Science 1996; 272: 1495-7.
20. Gomes E, Jakobsen MK, Axelsen KB, Geisler M, Palmgren MG. Chilling tolerance in Arabidopsis involves ALA1, a member of a new family of putative aminophospholipid translocases. Plant Cell 2000; 12: 2441-54.
21. Harris MJ, Ujhazy P, Ortiz D, Arias IM. Functional analysis of the familial intrahepatic cholestasis protein type 1 (FIC1). [Abstract] Hepatology 2001; 34: 266.
22. Ding J, Wu Z, Crider BP et al. Identification and functional expression of four isoforms of ATPase II, the putative aminophospholipid translocase. Effect of isoform variation on the ATPase activity and phospholipid specificity. J. Biol. Chem. 2000; 275: 23378-86.
23. Pomorski T, Lombardi R, Riezman H, Devaux PF, Van Meer G, Holthuis JC. Drs2p-related P-type ATPases Dnf1p and Dnf2p are required for phospholipid translocation across the yeast plasma membrane and serve a role in endocytosis. Mol. Biol. Cell 2003; 14: 1240-54.
24. Soubrane O, Gauthier F, DeVictor D et al. Orthotopic liver transplantation for Byler disease. Transplantation 1990; 50: 804-6.
25. Emond JC, Whitington PF. Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease). J. Pediatr. Surg. 1995; 30: 1635-41.
26. Kalicinski PJ, Ismail H, Jankowska I et al. Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass. Eur. J. Pediatr. Surg. 2003; 13: 307-11.
27. Kurbegov AC, Setchell KD, Haas JE et al. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 2003; 125: 1227-34.
28. Jacquemin E, Hermans D, Myara A et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25: 519-23.
29. Lykavieris P, van Mil S, Cresteil D et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J. Hepatol. 2003; 39: 447-52.
30. Eppens EF, van Mil SW, de Vree JM et al. FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. J. Hepatol. 2001; 35: 436-43.
31. Harris MJ, Arias IM. FIC1, a P-type ATPase linked to cholestatic liver disease, has homologues (ATP8B2 and ATP8B3) expressed throughout the body. Biochim. Biophys. Acta 2003; 1633: 127-31.
32. Harris MJ, Kagawa T, Dawson PA, Arias IM. Taurocholate transport by hepatic and intestinal bile acid transporters is independent of FIC1 overexpression in MDCK cells. J. Gastroenterol. Hepatol. 2004; 19: 819-25.
33. Pawlikowska L, Groen A, Eppens EF et al. A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum. Mol. Genet. 2004; 13: 881-92.
34. Chen F, Ananthanarayanan M, Emre S et al. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 2004; 126: 756-64.
35. Summerskill WHJ, Walsh JM. Benign recurrent intrahepatic obstructive jaundice. Lancet 1959; 2: 686-90.
36. Tygstrup N. Intermittent possibly familial intrahepatic cholestatic jaundice. Lancet 1960; 1: 1171-2.
37. Biempica L, Gutstein S, Arias IM. Morphological and biochemical studies of benign recurrent cholestasis. Gastroenterology 1967; 52: 521-35.
38. Bijleveld CM, Vonk RJ, Kuipers F, Havinga R, Fernandes J. Benign recurrent intrahepatic cholestasis: a long-term follow-up study of two patients. Hepatology 1989; 9: 532-7.
39. Tygstrup N, Steig BA, Juijn JA, Bull LN, Houwen RH. Recurrent familial intrahepatic cholestasis in the Faeroe Islands. Phenotypic heterogeneity but genetic homogeneity. Hepatology 1999; 29: 506-8.
40. Beaudoin M, Feldmann G, Erlinger S, Benhamou JP. Benign recurrent cholestasis. Digestion 1973; 9: 49-65.
41. Brenard R, Geubel AP, Benhamou JP. Benign recurrent intrahepatic cholestasis. A report of 26 cases. J. Clin. Gastroenterol. 1989; 11: 546-51.
42. Williams R, Cartter MA, Sherlock S, Scheuer PJ, Hill KR. Idiopathic recurrent cholestasis: a study of the functional and pathological lesions in four cases. Q. J. Med. 1964; 33: 387-99.
43. Schapiro RH, Isselbacher KJ. Benign recurrent intrahepatic cholestasis. N. Engl. J. Med. 1963; 268: 708-11.
44. Hopwood D, Read AE, Williams R. Ultrastructural findings in idiopathic recurrent cholestasis. Gut 1972; 13: 986-95.
45. Endo T, Uchida K, Amuro Y, Higashino K, Yamamura Y. Bile acid metabolism in benign recurrent intrahepatic cholestasis. Comparative studies on the icteric and anicteric phases of a single case. Gastroenterology 1979; 76: 1002-6.
46. Stark H. Benign recurrent cholestasis in a child. Pediatrics 1968; 41: 636-9.
47. Stathers G, Reed CS, Hirst E. Idiopathic recurrent cholestasis. Gastroenterology 1967; 52: 536-43.
48. Summerfield JA, Scott J, Berman M et al. Benign recurrent intrahepatic cholestasis: studies of bilirubin kinetics, bile acids, and cholangiography. Gut 1980; 21: 154-60.
49. Tygstrup N, Jensen B. Intermittent intrahepatic cholestasis of unknown etiology in five young males from the Faroe Islands. Acta Med. Scand. 1969; 185: 523-30.
50. van Ooteghem NA, Klomp LW, van Berge-Henegouwen GP, Houwen RH. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum. J. Hepatol. 2002; 36: 439-43.
51. Sinke RJ, Carlton VE, Juijn JA et al. Benign recurrent intrahepatic cholestasis (BRIC): evidence of genetic heterogeneity and delimitation of the BRIC locus to a 7-cM interval between D18S69 and D18S64. Hum. Genet. 1997; 100: 382-7.
52. Houwen RH, Baharloo S, Blankenship K et al. Genome screening by searching for shared segments: mapping a gene for benign recurrent intrahepatic cholestasis. Nat. Genet. 1994; 8: 380-6.
53. Floreani A, Molaro M, Mottes M et al. Autosomal dominant benign recurrent intrahepatic cholestasis (BRIC) unlinked to 18q21 and 2q24. Am. J. Med. Genet. 2000; 95: 450-3.
54. Kullak-Ublick GA, Kerb R, Mullhaupt B et al. A novel R432T mutation in the bile salt export pump gene (BSEP; ABCB11) is associated with recurrent intrahepatic cholestasis in an adolescent patient. Hepatology 2001; 34: 170A.
55. Balsells F, Wyllie R, Steffen R, Kay M. Benign recurrent intrahepatic cholestasis: improvement of pruritus and shortening of the symptomatic phase with rifampin therapy: a case report. Clin. Pediatr. (Phila) 1997; 36: 483-5.
56. Nakad A, Geubel AP, Lejeune D, Delannoy A, Bosly A, Dive C. Plasmapheresis: an effective therapy for cholestatic episodes related to benign recurrent intrahepatic cholestasis? Ann. Med. Interne (Paris) 1988; 139: 128-30.
57. Maggiore G, Bernard O, Riely CA, Hadchouel M, Lemonnier A, Alagille D. Normal serum gamma-glutamyl-transpeptidase activity identifies groups of infants with idiopathic cholestasis with poor prognosis. J. Pediatr. 1987; 111: 251-2.
58. Jansen PL, Strautnieks SS, Jacquemin E et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999; 117: 1370-9.
59. Arnell H, Nemeth A, Anneren G, Dahl N. Progressive familial intrahepatic cholestasis (PFIC): evidence for genetic heterogeneity by exclusion of linkage to chromosome 18q21-q22. Hum. Genet. 1997; 100: 378-81.
60. Strautnieks SS, Kagalwalla AF, Tanner MS, Gardiner RM, Thompson RJ. Locus heterogeneity in progressive familial intrahepatic cholestasis. J. Med. Genet. 1996; 33: 833-6.
61. Strautnieks SS, Kagalwalla AF, Tanner MS et al. Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. Am. J. Hum. Genet. 1997; 61: 630-3.
62. Strautnieks SS, Bull LN, Knisely AS et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 1998; 20: 233-8.
63. Ismail H, Kalicinski P, Markiewicz M et al. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr. Transplant. 1999; 3: 219-24.
64. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology 2001; 33: 1223-31.
65. Noe J, Stieger B, Meier PJ. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 2002; 123: 1659-66.
66. Gerloff T, Stieger B, Hagenbuch B et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 1998; 273: 10 046-50.
67. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002; 123: 1649-58.
68. Wang R, Salem M, Yousef IM et al. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Natl Acad. Sci. USA 2001; 98: 2011-16.
69. Wang L, Soroka CJ, Boyer JL. The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. J. Clin. Invest. 2002; 110: 965-72.
70. Kagawa T, Mochizuki K, Harris MJ, Watanabe N, Mine T, Matsuzaki S, Arias IM. Bile acid transport activity and intracellualr distribution of PFIC2 mutants in MDCKII cells coexpressing NTCP and BSEP. Hepatology 2003; 38: 475.
71. Plass JR, Mol O, Heegsma J et al. A progressive familial intrahepatic cholestasis type 2 mutation causes an unstable, temperature-sensitive bile salt export pump. J. Hepatol. 2004; 40: 24-30.
72. Jacquemin E, De Vree JM, Cresteil D et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120: 1448-58.
73. Deleuze JF, Jacquemin E, Dubuisson C et al. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996; 23: 904-8.
74. de Vree JM, Jacquemin E, Sturm E et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl Acad. Sci. USA 1998; 95: 282-7.
75. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999; 353: 210-11.
76. Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin. Liver Dis. 2001; 21: 551-62.
77. Van Nieuwkerk CM, Elferink RP, Groen AK et al. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996; 111: 165-71.
78. De Vree JM, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink RP. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000; 119: 1720-30.
79. Smit JJM, Schinkel AH, Oude-Elferink RPJ et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451-62.